European Journal of Heart Failure

Article	Citations
	1640
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	260
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices	146
Striving for the ‘perfect’ definition of iron deficiency in heart failure	145
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up	135
Letter regarding the article ‘Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair	127
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h	123
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	115
Heart failure: age is no excuse for complacency	108
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail	103
Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article ‘Medication adherence in patients with acutely decompensated heart failure	102
Abstract	100
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	99
Issue Information	89
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction	89
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	80
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure	76
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians	71
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management	71
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices	69
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock	67
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE	66
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato	65
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?	64
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials	64

Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology	63
Issue Information	63
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold	63
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases	63
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	62
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival	61
Abstract	61
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF	60
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	60
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC	59
Issue Information	59
Dissecting the heart failure phenotype through phenomics	59
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery	58
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial	58
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial	57
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	57
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial	57
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials	56
Issue Information	56
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	55
Correction to “Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence a	55
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities	55
Issue Information	55
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation	54
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’	54
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	54
Predicting survival in patients with severe heart failure: Risk score validation in the HELP‐HF cohort	53
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS‐HF trial	53
Letter regarding the article ‘Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction’	53
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure	52
	52
Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis	51
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models	51
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions	51
Corrigendum to ‘Congestion in heart failure: A circulating biomarker‐based perspective’ and articles listed below	51
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	49
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research	49
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	49
Letter regarding the article ‘Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and	49
Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles	48
Remote patient management of heart failure across the ejection fraction spectrum: A pre‐specified analysis of the TIM‐HF2 trial	47
Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction	47
Use of mechanical circulatory support in patients with non‐ischaemic cardiogenic shock	46
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy	46
The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial	45
Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction	45
Serial direct sodium removal in patients with heart failure and diuretic resistance	45
Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study	45
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis	45
The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis	43

Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE‐HF trial	43
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced	43
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	42
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors	42
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study	42
	41
Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes	41
Heart failure improvement, remission, and recovery: A European Journal of Heart Failure	41
Health status across major subgroups of patients with heart failure and preserved ejection fraction	41
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future	41
The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial	41
Reply to the letter regarding the article ‘Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines’	40
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	40
	40
Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article ‘Artificial intelligence and heart failure: A state‐of‐the‐art review’	40
The impact of early surgery on mortality in infective endocarditis complicated by heart failure – How much more data do we need?	40
Supplement Article	39
	39
An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction	39
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study	39
Issue Information	39
Clinical trials: conventional or pragmatic?	39
Late diagnosis in cancer sparks outrage—so why not heart failure?	39
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	38
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	38
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	38
Revolutionizing cardiogenic shock treatment: Is the microaxial flow pump the ultimate game changer?	38
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data	38
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?	38
Decreased left ventricular ejection fraction is associated with increased mortality in sepsis: A retrospective cohort study	38
Corrigendum to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction”	38
Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?	38
Low‐dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation – the RATE‐AF randomized trial	37
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF	37
Comparison of pulmonary congestion severity using artificial intelligence‐assisted scoring versus clinical experts: A secondary analysis of BLUSHED‐AHF	37
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria	37
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved	36
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction	36
Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC)	36
Video thermography uncovers relationship between volume status and temperature in heart failure	36
Disproportionate exercise‐induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non‐invasive echocardiographic study	36
Biventricular cardiac power reserve in heart failure with preserved ejection fraction	35
More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!	35
No longer from pillar to post: The first effective step in treating heart failure with preserved ejection fraction	35
Predicting heart failure: The promise of proteomics	35
Acute heart failure care – a consensus series of an international experts' group	35
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation	35
Letter regarding the article ‘Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction’	35
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial	35
Reply to ‘Is sodium chloride supplementation ready for clinical practice in acute heart failure?’	35
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudina	35
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry	34
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan	34
Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors – Insights from the ACTION‐MEMS study	34
The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry	34
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC	34
Trends in heart failure mortality in Sweden between 1997 and 2022	34
What's new in heart failure? October 2025	33
Issue Information	33
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	33
Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the	33
The heart during iron deficiency: a non‐rechargeable battery?	33
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	33
Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy	33
Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial	33
Reply to the letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’	32
Assessing health status after discharge for decompensated heart failure: a patient‐centred priority	32
Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial	32
Cardiac reverse remodelling with vericiguat: Victory or no victory?	32
Issue Information	32
	32
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta	32
Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney	32
Transcatheter edge‐to‐edge repair: fix the heart, heal the liver	32
Issue Information	31
Parvovirus B19 – more than a bystander in the prognosis of non‐ischaemic heart failure	31
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER	31
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure	31
Management of patients with heart failure at high risk of hyperkalaemia: The CARE‐HK in HF registry	31
End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)	31

Reply to the letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’	31
Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO‐HF trial	31
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF	31
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis	30
The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal	30
Early changes in renal function during rapid up‐titration of guideline‐directed medical therapy following an admission for acute heart failure	30
Clonal haematopoiesis of indeterminate potential is associated with progression of aortic valve stenosis	30
Correction to ‘What's new in heart failure? May–June 2024’, ‘What's new in heart failure? June–July 2024’, ‘What's new in heart failure? August–September 2024’, ‘The month in heart failure! September	30
Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE‐	30
Myocardial perfusion in cardiac amyloidosis	30
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry‐based analysis	29
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial	29
The addition of vericiguat to sacubitril/valsartan improved the composite endpoint. Add a finishing touch on heart failure medical therapy by vericiguat as secret ingredient	29
Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure	29
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Associatio	29
Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge‐to‐edge repair: Insights from EuroTR	29
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency	29
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction	29
Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial	28
Measures of left atrial function predict incident heart failure in a low‐risk general population: the Copenhagen City Heart Study	28
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases	28
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of	28
Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program	28
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy	27
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial	27
Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum	27
When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure	27
Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction	27
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	27
Reply to ‘Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in subjects with heart failure?’ Letter regarding the article ‘Impact o	27
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial	27
Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy	27
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	26
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the	26
Time to reconsider the perception and management of hypertensive heart disease	26
Implementing the evidence – the true summit of evidence‐based care and the false peak of guidelines	26
Reply to the letter regarding the article ‘Acute heart failure after non‐cardiac surgery: incidence, phenotypes, determinants and outcomes’	26
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial	26
Improve heart function to improve heart failure outcomes: the disease‐modifying effects of spironolactone	26
Sodium chloride supplementation in acute heart failure: A closer look at SOLVRED‐AHF. Letter regarding the article ‘Sodium chloride versus glucose solute as a volume replacement	26
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?	26
Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals	26
Worsening heart failure comes into focus, chronic heart failure takes a backseat	25
The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management	25
Bug attack! The rising importance of Chagas disease	25
Time to treat the climate and nature crisis as one indivisible global health emergency	25
Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows	25
If a patient does not require treatment with loop diuretics, do they really have heart failure?	25
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure – mechanism of action (SPONGE‐HF)	25
Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation	25
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis’	25
Peri‐procedural management of transcatheter mitral valve replacement in patients with heart failure	24
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge‐to‐edge repair – Results from the TriValve	24
Pacing beyond rhythm – improving myocardial function by tickling the heart electrically?	24
Transthyretin amyloidosis: the picture is getting clearer	24
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	24
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm A	24
Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out…?!	24
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	24
Growth differentiation factor‐15: A promising biomarker for early detection of pre‐heart failure	24
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease	24
Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction	24
Changes in natriuretic peptide levels following patiromer‐enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study	24
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis	24
Impact of misclassification bias on interpretation of finerenone efficacy in chronic obstructive pulmonary disease and heart failure with mildly reduced or preserved ejection fraction: A critical appr	23
Prioritizing prevention of de novo and worsening chronic heart failure	23
A second wind for digitalis glycosides in heart failure?	23
Letter regarding the article ‘Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with th	23
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61	22
Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction	22
Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension	22
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	22
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta‐analysis	22
	21
A Heart Team approach to contemporary device decision‐making in heart failure	21
Reply to: ‘What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?’	21
	21
Issue Information	21
Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes	21
Heart failure related central sympathetic activation: debunking the ‘holy grail’?	21
A machine‐learning‐based prediction model in patients with takotsubo syndrome: ‘You can't stop change any more than you can stop the suns from setting!’	21
	21
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left‐sided valvular heart disease in Europe. Insights from the ESC‐EORP Valvular	21
Kidney involvement in transthyretin cardiac amyloidosis – Role of urinary albumin to creatinine ratio and need for further evidence generation	20
Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure	20
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity	20
Left ventricular transthyretin amyloid load and apical sparing in patients with newly confirmed transthyretin amyloid cardiomyopathy	20
Glucagon‐like peptide‐1 receptor agonists across the cardiovascular‐kidney‐metabolic spectrum: One size does not fit all	20
Time for differential weight management in heart failure	20
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial	20
Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta‐analysis	20
Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure? Letter regarding the article ‘Impact of epicardia	20
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology	20
Residual tricuspid regurgitation after tricuspid transcatheter edge‐to‐edge repair: Insights into the EuroTR registry	20
Impact of malnutrition in patients with severe heart failure	20